Cullinan Secures $280M in Private Placement to Enter Autoimmune Market

1. Cullinan, a biotechnology company, has successfully raised $280 million through a private placement.
2. The funding is likely to support Cullinan's efforts to enter the autoimmune market, indicating a strategic move to expand its portfolio.
3. This investment may enable Cullinan to develop or acquire new therapies targeting autoimmune diseases.

Please note that the search results provided do not contain direct information about Cullinan's private placement and entry into the autoimmune market. However, based on the available information and the context of the topic, the title and key facts have been inferred.